Last reviewed · How we verify
PBA-0405
At a glance
| Generic name | PBA-0405 |
|---|---|
| Also known as | PB004.22.0405.aF |
| Sponsor | Pure Biologics S.A. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors (EARLY_PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PBA-0405 CI brief — competitive landscape report
- PBA-0405 updates RSS · CI watch RSS
- Pure Biologics S.A. portfolio CI